Brief · Use case · Market Access
JCA Cycle Outlook.
LiveOutlookProject how the next guidance or Joint Clinical Assessment cycle may move a product's EU access position, with the base rate, scenarios and early signposts.
JCA Cycle Outlook is a ready-made use case for Market Access. It ships under the Outlook template.
For policy and market access leads planning through a regulatory cycle. You get the quantity, horizon and resolution test first, a likelihood from a fixed scale with its base rate, a range, scenarios and the signposts to watch. Claims are cited or marked as gaps.
Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.
The decision
Will the next guidance or Joint Clinical Assessment cycle change the access position of a specialty product in the European Union, and how likely is it?
What the outlook examines
The Joint Clinical Assessment is new, so there is no long history to count. The outlook says so, uses the published guidance as its evidence, and states the likelihood with that limit.
| Part of the outlook | What it asks | Where it looks |
|---|---|---|
| What is in scope and when | Whether the product falls under joint clinical assessment, and from what date. Assessments began on 12 January 2025 for new cancer medicines and advanced therapies, extend to orphan medicines from 13 January 2028, and to all medicines from 13 January 2030.1 | Regulation (EU) 2021/2282. |
| What the method will accept | How the Coordination Group assesses comparisons. It adopted its methodological guideline on direct and indirect comparisons on 8 March 2024, and a guidance on the validity of clinical studies on 19 September 2024.2,3 | The Coordination Group’s guidelines. |
| What is still moving | Questions and answers on general methodological and procedural issues, which the Coordination Group published as late as May 2026 and which still point to the methodological guideline for indirect comparison.4 | The Coordination Group’s Q&A. |
What the outlook does
No base rate exists yet. The first assessments began in January 2025, so there is no history of outcomes to count. The outlook says this in the base rate section, uses analogous national processes as a reference class where it can, and labels the likelihood analyst judgment.1
A resolvable question. The outlook states what a change in access position means, in terms that can be checked, and by what date, so the projection can be scored later.
Signposts from the Coordination Group. The outlook watches for new guidance, revisions of the methodological guideline, and the annual work programme, and says what each would change.2,3,4
Scenarios. At Comprehensive length the outlook sets out the scenarios, for example that the cycle changes nothing for the product, changes the evidence it must hold, or changes the access route, each with a likelihood.
Recommended length
Comprehensive
The future could go several ways. Comprehensive adds the table of scenarios with their likelihoods.
You can pick another length on the form. The other two stay available.
Assumptions the outlook checks
The outlook states the assumptions its likelihood rests on and names the weakest one. Examples for this question:
- The product falls in the group of medicines that the cycle covers.
- The Coordination Group’s guidance cited is the version in force in the cycle.
- National processes continue to run beside the joint assessment as the regulation provides.
Standards, guidance and sources
The EU assessment framework
- Regulation (EU) 2021/2282 on health technology assessment: joint clinical assessments from 12 January 2025.1
- HTA Coordination Group, methodological guideline on direct and indirect comparisons, adopted 8 March 2024.2
- HTA Coordination Group, guidance on validity of clinical studies, adopted 19 September 2024.3
- HTA Coordination Group, questions and answers on general methodological and procedural issues, 15 May 2026.4
The decision practice behind the memo itself is on the template page.
What gets flagged
Any likelihood that rests on judgment because no base rate exists, any dependence on guidance that may be revised, and any scenario the outlook could not date.
What arrives
- The projection
- Starting point and base rate
- What is already in motion
- The most likely path
- Scenarios
- What would change it
- Signposts
- Confidence, and where it is weakest
What it will not do
It does not predict with certainty or recommend an action. The likelihood carries a range, confidence is stated separately, and a Decision Memo uses the outlook as an input.
It does not predict how an assessor will rate a product.
It does not predict with certainty. A likelihood is a statement about the evidence, with a range, and the outlook says how sure it is separately.
It does not make a base rate from nothing. Where no reference class exists, the base rate table says so and the likelihood is labeled analyst judgment.
It does not recommend an action. A Decision Memo takes the outlook as an input.
References
- [1] European Parliament and Council. Regulation (EU) 2021/2282 on health technology assessment. Application dates for medicinal products: 12 January 2025, 13 January 2028 and 13 January 2030. The phase-in dates are as given in the European Commission’s factsheet and EUR-Lex summaries; the regulation’s text was not read in full for this page.
- [2] HTA Coordination Group. Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons. Adopted 8 March 2024. Adoption date as given in the Coordination Group’s meeting report and Commission pages; the guideline was not read.
- [3] HTA Coordination Group. Guidance on Validity of Clinical Studies, version 1.0. Adopted 19 September 2024 (document dated 4 July 2024). Known from the Commission’s listing and search excerpts; not read.
- [4] HTA Coordination Group. Questions and Answers on general methodological and procedural issues. Dated 15 May 2026. Known from the Commission’s listing and search excerpts; not read.
Links checked 9 October 2026
These are the sources the template drew on. None of their authors or issuers has reviewed it.
About the Brief service
A Brief is a written answer from one specialist, at the depth you asked for. It arrives with its sources, and it closes by saying plainly what would change the conclusion. Nothing is hidden behind a summary, and anything the expert could not source is marked as a gap rather than filled in.
To edit a saved template, open New → Brief → From template, or the library rail on the service form.